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Persistent nontreponemal titers after treatment are common
among patients with early syphilis. We retreated 82 human
immunodeficiency virus–negative early syphilis participants
who were serofast at 6 months using benzathine penicillin.
Only 27% exhibited serological response after retreatment
and after an additional 6 months of follow-up.
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Early syphilologists noted that “the effective treatment of early
syphilis is one of the critical medical problems of modern times”
[1]. A continuing challenge to determining the response to treat-
ment of early syphilis is exemplified by the substantial propor-
tion of patients who fail to achieve serological cure and remain
serofast, defined as a <4-fold (2 dilution) decline in nontrepone-
mal antibody titers at 6–12 months or as persistently low titers
after treatment [2, 3]. Although retreatment is recommended for
serofast patients if follow-up cannot be ensured, optimal man-
agement remains uncertain due to the paucity of data regarding
serological response to retreatment and long-term outcomes.
We report results from a randomized, controlled clinical
trial in which 21% of human immunodeficiency virus
(HIV)–negative patients with early syphilis remained serofast
6 months after treatment [4]. We conducted additional analy-
ses of data from this trial to determine the serological response
of serofast patients after retreatment.
METHODS
Our randomized, controlled trial was conducted from June
2000 to March 2009 in North America and Madagascar
and involved HIV-negative patients ≥18 years with early syph-
ilis [4, 5]. The master protocol was approved by the University
of Alabama at Birmingham (UAB) Institutional Review Board
(IRB) and by IRBs serving each study site.
Eligibility criteria, procedures for enrollment and follow-up,
and definitions for primary and secondary were previously de-
scribed [4, 5]. Participants were diagnosed with early latent
(EL) syphilis based on either a nonreactive syphilis serology or
documented exposure to a sexual partner with primary or sec-
ondary syphilis within the preceding 12 months. All partici-
pants were required to have reactive rapid plasma reagin
(RPR) antibody tests at enrollment. Participants without peni-
cillin (PCN) allergy received initial treatment with 2.4 million
units of intramuscular (IM) benzathine PCN or 2.0 g azithro-
mycin (AZM) orally as directly observed therapy. RPR titers at
the baseline visit prior to therapy and at the 6- and 12-month
visits were performed at the UAB central laboratory according
to standards [6].
Serological cure at 6 months following therapy was defined
as either a negative RPR or ≥4-fold (2 dilution) decrease in
titer. Seroreversion was defined as becoming RPR negative
after therapy. Serofast status was defined as either no change
in RPR titer or a 2-fold (1 dilution) decrease or increase in
titer following initial therapy or retreatment. Per protocol, all
participants determined to be serofast at 6 months after initial
treatment with PCN or AZM were retreated with 1 dose of 2.4
million units of benzathine PCN IM at the 6-month visit.
These analyses were performed on the subset of the original
per-protocol cohort who were serofast at 6 months after initial
therapy, received retreatment, and had serological data at the
12-month visit. Proportions of participants with seroreversion,
serological cure, or serofast status after retreatment were deter-
mined at 12 months using the definitions above. Participants
who achieved serological cure after retreatment and those who
remained serofast were compared for age and baseline and 6-
month RPR titers using a Wilcoxon 2-sample test, and were
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compared for gender, geometric mean RPR titers, initial treat-
ment regimen, and stage using a chi-square test.
RESULTS
We identified 82 HIV-negative adults with early syphilis who
were serofast at 6 months after initial treatment with benza-
thine PCN (n = 41) or AZM (n = 41). Their median age was
29 years (range, 18–47), and most were male (55%), heterosex-
ual (95%), and of Malagasy (88%) origin. Fourteen (17%) se-
rofast participants had primary syphilis, 25 (31%) had
secondary syphilis, and 43 (52%) had EL syphilis. At 6
months after initial treatment, the modal RPR titer among the
82 participants was 1:16 (n = 19, 23%), with a range from 1:1
to 1:1024.
After retreatment with benzathine PCN, only 11 (13%) par-
ticipants exhibited a ≥4-fold decline in RPR titers from their
6-month titers, and 71 (87%) remained serofast at 12 months
(P < .0001). However, when serological response was deter-
mined relative to baseline titers before initial treatment, 22
(27%) participants had achieved serological cure and 60 (73%)
were serofast (P < .0001). Of those with serological response
following retreatment, only 2 had seroreversion to a nonreac-
tive RPR at the 12-month follow-up.
Gender, age, stage of syphilis, and initial treatment regimen
were not associated with likelihood of achieving serological
cure after retreatment (Table 1). However, there were statisti-
cally significant differences in the baseline and 6-month RPR
titers between patients with serological cure vs serofast status.
The median baseline RPR titer among the former was 1:32
compared with the median baseline titer of 1:8 among serofast
patients (P < .01). There were similar differences in RPR titers
at the 6-month visit between groups; participants with sero-
logical cure had a higher median RPR titer prior to retreat-
ment than did participants who remained serofast at 12
months (Table 1). Furthermore, geometric mean RPR titers
were significantly different between patients with serological
cure vs serofast status at baseline and at 6 months (Table 1).
DISCUSSION
Despite retreatment with 2.4 million units benzathine PCN,
73% of patients with early syphilis who failed to achieve sero-
logical cure at 6 months after initial therapy remained serofast
at 12 months. Patients with early syphilis who had higher
nontreponemal titers at baseline and at 6 months (≥1:32)
were more likely to exhibit serological cure after retreatment
than those with lower titers. Among the patients who were se-
rofast at 6 months, only a small proportion exhibited serore-
version after retreatment. Our findings illustrate the minimal
improvement in serological response among serofast patients
retreated with a single dose of PCN, especially those with
lower RPR titers (≤1:16) at baseline or prior to retreatment.
Assessing the biological significance of the serofast state is
difficult; stable nontreponemal antibody titers following
therapy could represent persistent low-level infection with
Treponema pallidum, variability of host response to infection,
or possibly other confounding nontreponemal inflammatory
conditions in the host. Nontreponemal tests measure immu-
noglobulin M (IgM) and IgG antibodies to T. pallidum and
potentially to lipoidal and cardiolipin material released from
damaged host cells during syphilis infection, which may also
result from other illnesses that can produce tissue damage [7].
Although nontreponemal antibody titers generally correlate
with syphilitic stage/disease activity [3], the implications of
high titers (eg, 1:32) vs low titers in the serofast state are
unknown. However, consistent with our previous analyses [4],
these findings suggest that higher nontreponemal titers at
retreatment are associated with a higher probability of serolog-
ical response to therapy.
Clinical management of patients who remain serofast after
treatment or retreatment for early syphilis is challenging.
Treatment failure, which is usually defined as a sustained
Table 1. Characteristics and Serological Outcomes of Serofast
Patients With Early Syphilis Retreated With Benzathine Penicillin
Characteristic
Outcome at 12 Months After






Gender (n, % male) 13, 59% 32, 53%
Age (25th, 50th, and
75th percentiles)
23, 25, 36 23, 30, 36
RPR titers (25th, 50th,
and 75th percentiles)
Baseline 1:16, 1:32, 1:128 1:4, 1:8, 1:32*
6 months 1:16, 1:32, 1:64 1:4, 1:8, 1:16**
RPR titers (geometric
mean titer [95% CI])
Baseline 34 (19, 62) 10 (8, 14)***
6 months 26 (13, 52) 8 (6, 11)****
Syphilis stage (n, %)
Primary 5, 23% 9, 15%
Secondary 6, 27% 19, 32%
Early latent 11, 50% 32, 53%
Initial treatment (n, %)
Penicillin 12, 55% 29, 48%
Azithromycin 10, 46% 31, 52%
Abbreviations: CI, confidence interval; RPR, rapid plasma regain.
Wilcoxon 2-sample test: *P = .0004; **P = .001. T test: ***P = .0002;
****P = .0005.
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4-fold increase in nontreponemal titers after therapy, is con-
sidered to be an indication for cerebrospinal fluid (CSF) exam-
ination for T. pallidum involvement [3]. However, some
experts also recommend CSF examination for patients who do
not demonstrate serological response after treatment (≥4-fold
decrease in nontreponemal test titer or sustained seroreversion
occurring within 6 months of treatment) [6]. Following these
recommendations, 60 participants (13% of the 465 partici-
pants in the original study) [4] who remained serofast despite
retreatment would have been considered for lumbar puncture
to rule out neurosyphilis.
Our study provides the first evaluation of serological out-
comes following retreatment of participants with the syphilis
serofast state. However, we provided only 1 dose of benzathine
PCN for retreatment, although the recommended therapy for
patients with suspected treatment failure is 2.4 million units of
benzathine PCN weekly for 3 weeks unless neurosyphilis is
present [3]. We had a modest sample size of persons who re-
ceived retreatment, and we did not conduct CSF examinations
of serofast patients at the 12-month visit. However, none of
the participants available for follow-up exhibited symptoms
suggestive of neurosyphilis during the study period. Only 23
of our participants who were serofast at 12 months returned
for additional follow-up at 18 and 24 months after initial
treatment, which limited further analysis. Long-term out-
comes after retreatment require further investigation, as does
the applicability of our observations to persons with syphilis
and HIV co-infection. Another limitation of our data is the
lack of a comparison group by which to determine the expect-
ed decline in nontreponemal titers among serofast patients in
the absence of retreatment. Thus, we cannot rule out that the
seroreversion/serological cure exhibited by 24% of our partici-
pants may have been due to the natural decline in RPR titers
after initial therapy, rather than due to the additional dose of
benzathine PCN.
Prior to our study, there had been no evidence that patients
who fail to exhibit an appropriate 4-fold decline in titers
should receive additional courses of therapy for syphilis,
though this is often done in clinical practice. Our results
suggest that the incremental benefit of retreating HIV-negative
serofast patients with early syphilis is marginal, considering
the 1:3 ratio of serological response to serofast state at follow-
up despite retreatment. Further, prospectively designed studies
are needed; and our findings provide a starting point for
addressing the unresolved questions about the serofast state
and its management. At present, the management of individu-
al serofast patients will continue to require clinical judgment,
consideration of nontreponemal antibody titers, underlying
medical conditions such as HIV infection, and/or the likeli-
hood that the patient will return for subsequent serological
monitoring after treatment.
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